Related Post
- Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 - March 18th, 2024
- TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region - March 18th, 2024
- RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit - March 18th, 2024
- Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset... - March 18th, 2024
- Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics... - March 18th, 2024
- Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with... - March 18th, 2024
- Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024 - March 18th, 2024
- PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual... - March 18th, 2024
- Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin - March 18th, 2024
- Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 18th, 2024
- Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - March 18th, 2024
- QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements - March 18th, 2024
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - March 18th, 2024
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates - March 18th, 2024
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights - March 18th, 2024
- Homology Medicines Declares Distribution to Common Stockholders - March 18th, 2024
- Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 - March 18th, 2024
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - March 18th, 2024
- Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million - March 18th, 2024
- QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy - March 18th, 2024
- BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual... - March 17th, 2024
- Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3 - March 17th, 2024
- University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - March 17th, 2024
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 17th, 2024
- Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results - March 17th, 2024
- Nuvectis Pharma to Present at the 36th Annual Roth Conference - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - March 17th, 2024
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - March 17th, 2024
- Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million - March 17th, 2024
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity - March 17th, 2024
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - March 17th, 2024
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - March 17th, 2024
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement... - March 17th, 2024
- Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - March 17th, 2024
- Sanofi: Information concerning the total number of voting rights and shares - February 2024 - March 17th, 2024
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - March 17th, 2024
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - March 17th, 2024
- Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - March 17th, 2024
- NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence - March 17th, 2024
- Financière de Tubize - Annual report 2023 - March 17th, 2024
- ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - March 15th, 2024
- Rick Simpson Oil California Introduces RSO Suppositories A New Path to Wellness Through Direct Absorption - March 15th, 2024
- Sino Biological Announces Services Partnership with Rapid Novor - March 15th, 2024
- Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy - March 15th, 2024
- HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell - March 15th, 2024
- IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights - March 15th, 2024
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update - March 15th, 2024
- Vaxart Provides Business Update and Reports Full Year 2023 Financial Results - March 15th, 2024
- Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - March 15th, 2024
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update - March 15th, 2024
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development - March 15th, 2024
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates - March 15th, 2024
- Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update - March 15th, 2024
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic... - March 15th, 2024
- Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 - March 15th, 2024
- Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024 - March 15th, 2024
- Digicann Ventures Announces Granting of Forbearance for Convertible Debenture Maturity Date - March 15th, 2024
- TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024 - March 15th, 2024
- Common Skin Cancer, Like Christie Brinkley’s, Can Often Be Cured Without Surgery - March 15th, 2024
- Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and... - March 15th, 2024
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge - March 13th, 2024
- Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million - March 13th, 2024
- Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress - March 13th, 2024
- Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya - March 13th, 2024
- Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004 - March 13th, 2024
- Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study - March 13th, 2024
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings - March 13th, 2024
- Neurona Therapeutics to Present at Stifel 2024 Virtual CNS Days - March 13th, 2024
- Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering - March 13th, 2024
- Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days - March 13th, 2024
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results - March 13th, 2024
- SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 - March 13th, 2024
- MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance - March 13th, 2024
- Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 13th, 2024
- Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024 - March 13th, 2024
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome - March 13th, 2024
- Cronos Group Inc. to Speak at the 36th Annual Roth Conference - March 13th, 2024
- IMUNON Announces Leadership Change - March 13th, 2024
- iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call - March 13th, 2024
- Scorpius Holdings, Inc. Announces Closing of Public Offering - March 13th, 2024
Recent Comments